ZVRA
Zevra Therapeutics, Inc. NASDAQ Listed Apr 16, 2015$11.25
After hrs
$11.22
-0.27%
Mkt Cap $665.0M
52w Low $7.16
68.2% of range
52w High $13.16
50d MA $9.67
200d MA $9.44
P/E (TTM)
7.2x
EV/EBITDA
5.0x
P/B
3.6x
Debt/Equity
0.4x
ROE
53.8%
P/FCF
-203.7x
RSI (14)
—
ATR (14)
—
Beta
0.89
50d MA
$9.67
200d MA
$9.44
Avg Volume
1.0M
About
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disea…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | 0.05 | 1.16 | +2201.6% | 9.12 | +20.1% | +21.3% | +14.1% | +11.7% | +9.4% | +8.2% | — |
| Nov 5, 2025 | AMC | -0.02 | -0.01 | +50.0% | 10.07 | -5.7% | -9.7% | -12.5% | -9.6% | -6.4% | -6.7% | — |
| Aug 12, 2025 | AMC | 2.19 | 1.21 | -44.7% | 11.76 | -12.1% | -19.8% | -24.3% | -19.8% | -21.8% | -23.4% | — |
| May 13, 2025 | AMC | -0.21 | -0.06 | +71.4% | 7.87 | +8.0% | +3.4% | +7.1% | +10.0% | +13.2% | +9.4% | — |
| Mar 11, 2025 | AMC | -0.39 | -0.67 | -71.8% | 8.07 | -0.6% | -1.9% | -1.6% | +3.0% | +3.5% | -1.2% | — |
| Nov 12, 2024 | AMC | -0.44 | -0.69 | -56.8% | 8.57 | -5.7% | +1.1% | +5.4% | +0.6% | +0.4% | +4.7% | — |
| Aug 13, 2024 | AMC | -0.47 | -0.48 | -2.1% | 6.78 | -1.0% | +3.1% | +5.2% | +8.7% | +4.4% | +11.9% | — |
| May 8, 2024 | AMC | -0.49 | -0.40 | +18.4% | 5.16 | +0.6% | -2.5% | -6.6% | -5.2% | -7.0% | -6.6% | — |
| Mar 28, 2024 | AMC | -0.20 | -0.40 | -100.0% | 5.80 | -11.2% | -11.0% | -11.7% | -13.3% | -15.3% | -16.9% | — |
| Nov 7, 2023 | AMC | -0.29 | -0.40 | -37.9% | 4.40 | +2.5% | +0.9% | -4.5% | -5.7% | -5.9% | -0.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.07 | $9.50 | -5.7% | -9.7% | -12.5% | -9.6% | -6.4% | -6.7% |
| Nov 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.07 | $9.50 | -5.7% | -9.7% | -12.5% | -9.6% | -6.4% | -6.7% |
| Aug 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $11.76 | $10.34 | -12.1% | -19.8% | -24.3% | -19.8% | -21.8% | -23.4% |
| Jul 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.56 | $11.94 | +3.3% | +4.0% | +8.4% | +10.6% | +10.6% | +6.6% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.87 | $8.50 | +8.0% | +3.4% | +7.1% | +10.0% | +13.2% | +9.4% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.92 | $7.84 | -1.0% | +0.3% | +4.9% | +5.4% | +0.6% | +0.4% |
| Mar 13 | Guggenheim | Maintains | Buy → Buy | — | $7.92 | $7.84 | -1.0% | +0.3% | +4.9% | +5.4% | +0.6% | +0.4% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.92 | $7.84 | -1.0% | +0.3% | +4.9% | +5.4% | +0.6% | +0.4% |
| Mar 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.07 | $8.02 | -0.6% | -1.9% | -1.6% | +3.0% | +3.5% | -1.2% |
| Mar 12 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $8.07 | $8.02 | -0.6% | -1.9% | -1.6% | +3.0% | +3.5% | -1.2% |
Recent Filings
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
ZVRA likely gained a significant partnership or licensing deal with Commave Therapeutics, potentially accelerating product development and expanding its revenue pipeline through collaboration.
Mar 16
8-K · 5.02
!!! Very High
Zevra Therapeutics, Inc. -- 8-K 5.02: Executive Change
Zevra Therapeutics appointed Justin Renz as Chief Financial Officer while he resigned from the board, effective March 9, 2026, signaling potential leadership restructuring.
Mar 9
Data updated apr 27, 2026 11:54am
· Source: massive.com